Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR

Rhea-AI Summary

Equillium, Inc. (Nasdaq: EQ) has announced positive results from its EQUATE study on Itolizumab, a targeted therapy for acute graft-versus-host disease (aGVHD). The presentation at the American Society of Transplantation and Cellular Therapy showed high clinical response rates with a 70% reduction in steroid use at Day 29 and a remarkable 99% taper at Day 169. These findings suggest potential for Itolizumab as a first-line treatment in severe aGVHD, with the initiation of the pivotal Phase 3 EQUATOR study.

Dr. Koreth emphasized the significance of these results, considering the lack of approved first-line treatments for aGVHD.

Positive

• High clinical response rates for Itolizumab in treating aGVHD.
• Responders experienced a 70% taper in steroid use by Day 29, and 99% by Day 169.
• The study showed promise for Itolizumab as a first-line therapy in severe aGVHD.
• Initiation of the EQUATOR pivotal Phase 3 study for Itolizumab.

Negative

• None.

Itolizumab was associated with high clinical response rates at Day 15 and 29​

Responders were able to taper steroids by 70% at Day 29 and 99% at Day 169​

Itolizumab being evaluated in pivotal Phase 3 EQUATOR study in first-line acute graft-versus-host disease

LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an oral presentation was given yesterday afternoon at the Tandem Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research.

The oral presentation, given by Dr. John Koreth, associate professor of medicine, Dana Farber Cancer Institute, Harvard Medical School, highlights positive final study results, including long-term follow-up data for up to one year, from EQUATE (NCT03763318), a Phase 1b study of itolizumab in combination with corticosteroids (CS) to treat subjects with newly diagnosed severe acute graft-versus-host disease (aGVHD). The data demonstrate promising outcomes in subjects with severe aGVHD. Equillium has since initiated EQUATOR (NCT05263999), a pivotal Phase 3 study of itolizumab as a potential initial therapy for aGVHD in combination with CS.

“Acute GVHD is a potentially lethal condition with no drugs approved for the first-line treatment setting,” said Dr. Koreth. “Twelve-month findings from the study support the potential clinical value of itolizumab as an initial treatment for patients with high-risk aGVHD, demonstrate high complete response rates that are both rapid and durable and compare favorably to historical data with corticosteroid therapy alone. Importantly, these findings demonstrated that responders to itolizumab treatment had a clinically meaningful reduction in the use of corticosteroid of ninety-nine percent at six months.”

Title: Final Safety and Efficacy Results from EQUATE, an Open-Label Study Evaluating Itolizumab, a Novel Targeted anti-CD6 Therapy, in Newly Diagnosed Acute Graft-Versus-Host Disease
Presenting Author: Dr. John Koreth
Abstract ID Number: 36
Assigned Session: Oral Abstract - Session E: GVHD - Clinical

Key Highlights, Summary and Conclusions from Presentation:

• Itolizumab treatment in combination with systemic corticosteroids was associated with rapid and durable high rates of overall clinical response​
• Response at Day 29 was associated with improved progression-free survival through 1 year​
• Responders were able to taper steroids by 70% at Day 29 and 99% at Day 169​
• Itolizumab was safe and well tolerated in severe aGVHD patients
• Itolizumab offers a favorable benefit-risk profile that supports evaluation in the pivotal Phase 3 study (EQUATOR), which has been initiated for the first-line treatment of aGVHD

The oral presentation is available on the Presentations page of Equillium’s website.

About Graft-Versus-Host Disease (GVHD)

GVHD is a multisystem disorder that is a common complication of allogeneic hematopoietic stem cell transplants (allo-HSCT) caused by the transplanted immune system recognizing and attacking the recipient’s body. Symptoms of GVHD include rash, itching, skin discoloration, nausea, vomiting, diarrhea, and jaundice, as well as eye dryness and irritation.

GVHD is the leading cause of non-relapse mortality in cancer patients receiving allo-HSCT, and its risk limits the number and type of patients receiving HSCT. GVHD results in high morbidity and mortality, with five-year survival of approximately 53% in patients who respond to steroid treatment and mortality as high as 95% in patients who do not respond to steroids. There are no approved treatments for first-line aGVHD. Published literature (MacMillan et al., 2015) describes background response rates to high-dose steroid administration in severe high-risk patients as 43% overall response and 27% complete response.

About the EQUATE Study

The EQUATE study is a Phase 1b/2 trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of itolizumab for first-line treatment in patients who present with aGVHD (NCT03763318). The Phase 1b part of the trial is an open-label dose escalation study in adult patients who present with high-risk aGVHD and typically respond poorly to steroids. The Phase 1b data informed the selection of the dose being used in the EQUATOR pivotal Phase 3 study.

About Itolizumab

Itolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM signaling pathway to selectively downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases.

About Equillium

Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of the following novel first-in-class immunomodulatory assets targeting immuno-inflammatory pathways. EQ101: a tri-specific cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15; currently under evaluation in a Phase 2 proof-of-concept study of patients with alopecia areata. EQ102: a bi-specific cytokine inhibitor that selectively targets IL-15 and IL-21; currently under evaluation in a Phase 1 study to include healthy volunteers and celiac disease patients. Itolizumab: a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells; currently under evaluation in a Phase 3 study for patients with acute graft-versus-host disease (aGVHD) and a Phase 1b study for patients with lupus/lupus nephritis. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited and has entered a strategic partnership with Ono Pharmaceutical Co., Ltd. for the development and commercialization of itolizumab under an exclusive asset purchase agreement.

For more information, visit www.equilliumbio.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", “could”, “continue”, "expect", "estimate", “may”, "plan", "outlook", “future” and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to statements regarding the benefit of treating patients with aGVHD with itolizumab and Equillium’s plans for developing itolizumab. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical studies; whether the results from clinical studies will validate and support the safety and efficacy of Equillium’s product candidates; and risks related to Ono’s financial condition, willingness to continue to fund the development of itolizumab, and decision to exercise, if ever, its option to purchase itolizumab or terminate the asset purchase agreement. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website at www.sec.gov and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230217005036/en/

Investor & Media Contact

Equillium, Inc.

Michael Moore

Vice President, Investor Relations Officer & Head of Corporate Communications

619-302-4431

ir@equilliumbio.com

Source: Equillium, Inc.

FAQ

What are the clinical response rates for Itolizumab in the EQUATE study?

Itolizumab demonstrated high clinical response rates at Day 15 and 29 in the EQUATE study.

What is the significance of the 99% steroid taper at Day 169 for Itolizumab?

The 99% steroid taper at Day 169 indicates a significant reduction in steroid dependence, showcasing Itolizumab's effectiveness in treating severe aGVHD.

When was the EQUATOR Phase 3 study for Itolizumab initiated?

The EQUATOR Phase 3 study for Itolizumab was initiated following the promising results from the EQUATE study.

What condition does Itolizumab target in the clinical trials?

Itolizumab is being evaluated for its effectiveness in treating acute graft-versus-host disease (aGVHD).

Who presented the findings of the EQUATE study?

The findings of the EQUATE study were presented by Dr. John Koreth from Dana Farber Cancer Institute.